Who are Nicotine Mini-Lozenge for 11 Months's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): nicotine patch plus nicotine gum/lozenge, Combination Bupropion + NRTs, Pre-Quit Nicotine Gum, Nicotine replacement, bupropion + lozenge, Patch, Nicotine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotine-mini-lozenge-for-11-months.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nicotine Mini-Lozenge for 11 Months — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nicotine Mini-Lozenge for 11 Months (Nicotine Mini-Lozenge for 11 Months) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT). Area: Smoking Cessation / Addiction Medicine.

marketed Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT) Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Nicotine Mini-Lozenge for 11 Months (Nicotine Mini-Lozenge for 11 Months) — University of Wisconsin, Madison. Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nicotine Mini-Lozenge for 11 Months TARGET	Nicotine Mini-Lozenge for 11 Months	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
nicotine patch plus nicotine gum/lozenge	nicotine patch plus nicotine gum/lozenge	University of Minnesota	marketed	Nicotine replacement therapy (NRT) combination	Nicotinic acetylcholine receptors
Combination Bupropion + NRTs	Combination Bupropion + NRTs	Brentwood Biomedical Research Institute	marketed	Antidepressant + nicotine replacement combination	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine replacement	Nicotine replacement	Instituto Fernandes Figueira	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
bupropion + lozenge	bupropion + lozenge	University of Wisconsin, Madison	marketed	Antidepressant + nicotine replacement therapy	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
Patch, Nicotine	Patch, Nicotine	Assistance Publique - Hôpitaux de Paris	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT) class)

University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nicotine Mini-Lozenge for 11 Months — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine-mini-lozenge-for-11-months. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab